Verano Holdings (VRNO) Share-based Compensation (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Share-based Compensation of $2.2 million for Q1 2026, down 33.12% year-over-year from $3.3 million in Q1 2025, and down 80.8% quarter-over-quarter from $11.5 million in Q4 2025.
Verano Holdings (VRNO) Share-based Compensation (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Share-based Compensation for 6 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 33.12% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $10.4 million (down 36.2% YoY), while the FY2025 annual figure was $11.5 million, down 32.1% from the prior year.
- Share-based Compensation fell to $2.2 million in Q1 2026 per VRNO's latest filing, from $11.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $27.1 million in Q1 2022 and bottomed at -$9.0 million in Q4 2023.
- Historically, Share-based Compensation has averaged $4.1 million across 5 years, with a median of $3.9 million in 2024.
- Annual changes were most pronounced in 2023 — Share-based Compensation plunged 285.94% — and 2024, when it soared 622.06%.
- Verano Holdings' Share-based Compensation stood at $4.8 million in 2022, then slumped by 285.94% to -$9.0 million in 2023, then soared by 143.57% to $3.9 million in 2024, then jumped by 194.12% to $11.5 million in 2025, then plunged by 80.8% to $2.2 million in 2026.
- Business Quant data shows VRNO's Share-based Compensation at $2.2 million in Q1 2026, $11.5 million in Q4 2025, and -$6.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Verano Holdings | 433.71 Mn | 348.51 Mn | 99.70 Mn | 5.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.70 Mn |
| Jun 30, 2026 | 5.70 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 11.51 Mn |
| Dec 31, 2025 | 11.51 Mn |
| Sep 30, 2025 | -6.64 Mn |
| Sep 30, 2025 | -6.64 Mn |
| Jun 30, 2025 | 3.34 Mn |
| Jun 30, 2025 | 3.34 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 3.91 Mn |
| Dec 31, 2024 | 3.91 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Mar 31, 2024 | 3.93 Mn |
| Mar 31, 2024 | 3.93 Mn |